4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to 4D Molecular Therapeutics webcast presentation of interim data from the 4D-150 Phase 2 PRISM dose expansion cohort in wet AMD patients with severe disease activity and high treatment burden. (Operator Instructions)
As a reminder, today's call is being recorded. With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.
Thank you, operator, and welcome to our webcast. We issued a press release describing the 4D-150 PRISM clinical trial interim results on Saturday, February 3. And the recording of this webcast will be accessible in the Investors section of the 4DMT website after the completion of this call today.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Bob Kim, our Chief Medical Officer; and Dr. Arshad Khanani from Sierra Eye Associates and a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |